Skip to content

Repeat Nasal Allergen Challenge

Assessment of Inflammatory Mediator and Cellular Changes Following Repeated Nasal Allergen Challenge in Subjects With Allergic Rhinitis Sensitive to Timothy Grass Pollen - a Validation Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00290368
Enrollment
22
Registered
2006-02-13
Start date
2006-02-28
Completion date
2006-05-31
Last updated
2023-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hayfever

Keywords

Nasal allergen challenge, Allergic rhinitis, Timothy grass pollen, inflammatory mediators

Brief summary

This is a non-drug, biomarker study to assess the utility of the model of repeated nasal allergen challenges in subjects with atopic rhinitis as a method of inducing an increased response to inhaled allergen, which will more closely resemble the responses seen during the hayfever season.

Detailed description

This is a non-drug, biomarker study to assess the utility of the model of repeated nasal allergen challenges in subjects with atopic rhinitis as a method of inducing an increased response to inhaled allergen, which will more closely resemble the responses seen during the hayfever season.

Interventions

PROCEDURESkin Prick Test
PROCEDURENasal filter paper placement
PROCEDURENasal lavage
PROCEDURENasal scrape
PROCEDURENasal symptoms score

Sponsors

Novartis Pharmaceuticals
CollaboratorINDUSTRY
Imperial College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

1. Male and female subjects with a history of seasonal (intermittent) atopic rhinitis, aged 18-40 years. 2. Otherwise healthy with no health problems that may jeopardize the subjects participating in the study, absence of history of other significant allergies.

Exclusion criteria

1. Smokers (use of tobacco products in the previous 3 months). 2. Presence of any respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function (FEV1 \> 80% predicted at screening).

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026